Skip to main content

Table 3 Multivariate analysis of prognostic factors for overall survival and progression-free survival

From: Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study

Factor

OS

 

PFS

HR

P Value

 

HR

P Value

Sex (female vs. male)

0.976

0.925

 

0.668

0.156

Age

1.01

0.229

 

1.011

0.189

Mean tumor diameter (cm)

1.02

0.572

 

1.003

0.932

Albumin g/dL

1.002

0.915

 

1.053

0.027

Total bilirubin u mol/L

1.008

0.45

 

1.012

0.239

AFP > 400 ng/mL

1.755

0.006

 

1.456

0.082

BCLC B

1.563

0.109

 

0.28

0.104

Hepatitis B

0.898

0.737

 

0.433

0.012

TACE-RFA

0.461

0

 

0.213

< 0.001

  1. OS overall survival, PFS progression-free survival, HR hazard ratio, AFP alpha-fetoprotein, BCLC Barcelona Clinic Liver Cancer, RFA radiofrequency ablation, TACE transarterial chemoembolization
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us